Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
wow you fell off a cliff and about to be non-compliant with nasdaq, like SINT, FAZE, and NEGG. hahaha
This has to be the most incompetent pharma companies on the planet. actually worth less with a novel drug approved to market and selling. Goldman Sachs calling for a 'sell'. tipranks with the lowest score ever, a 1. this management is horrible. i hope to god there is a buyout in the works before seres leadership bankrupts this company
would love to hear any thoughts as to why this can't seem to get any positive attention even after FDA approval. They haven't filed the $125M from Nestle yet, I'm wondering if they're in discussions for buyout.
Ok, what's the word on the street here? Is Nestle going to buy Seres out or what? Either way, the PPS does not reflect the projected $750M/year of annual sales of this recently FDA approved drug. Some are saying the price is being held back for options to expire worthless on the 17th (this coming wednesday). Not sure what to make of all this except that it is following the same pattern as PRVB before buyout and the PRVB drug is not near as efficacious for DM as Seres' drug is for c diff.
MCRB Perverse mkt action now. Candidate passed PDUFA and has great mkt potential. Rollout in June.
MCRB is partners with Nestle and many looking to an outright buyout.
Another candidate coming up in May.
I will hold and wait for eventual payday.
ARNA did that in the past- an offering just before its big (successful) events.(ADCOM, PDUFA)
Why would they use debt financing rather than do a share offering? They should have 8k a share offering months ago and then let it run and sell shares into the run. Approval was not guaranteed but at least position the company to take advantage of it.
MCRB Another comment from another forum
killbilltrader
19m
$MCRB Buying all day with both hands. Derisked, partnership, royalties well positioned for growth.
Bullish
MCRB Reprinted from another forum
CO145
$MCRB At the current price of $5.90/shr, this is trading at $565M market cap net of cash. pretty silly for a drug with a $1b US potential and $2B global potential plus a solid pipeline. The market cap will triple
MCRB Good morning all.
Sold 20% @ high of AH session (7.00)
Just rebot more @ 6.04
MCRB We are #2 Trending, after META.
Ours is a low price bio, catnip for the "boys" in the morning.
Hold on. We are going go higher tomorrow.
$MCRB Seres Therapeutics Inc
Closed today @ $6.40 +$0.24 (3.90%)
After Hours snapshot (up another .47)
Bid ARCX 6.85 x 5 Ask ARCX 6.87 x 29
Volume 6,027,253
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
MCRB I think we'll see some lift tomorrow.
The likelihood of a buyout from Nestle is very good. Could come soon.
Not a bad stock to hang in with. Another in the pipeline coming up.
GL Cosa!
US FDA approves Seres Therapeutics' pill for deadly C. difficile infections
REUTERS
https://stockcharts.com/h-sc/ui?s=MCRB
April 26 (Reuters) - The U.S. health regulator on Wednesday approved Seres Therapeutics Inc's (MCRB) pill for treating a type of bacterial infection, giving an easier and standardized option to patients who often have to rely on individual donors for fecal transplants. (Reporting by Raghav Mahobe and Aditya Samal in Bengaluru; Editing by Shinjini Ganguli)
I though it would have a greater immediate impact on SP.
MCRB Ok, news out. It passed!
No action yet but here is my post on ST
MiamiGent
2m
$MCRB It will slowly and gradually rise here in AH.
Wait for tomorrow. News will be out. The "boys" will latch on to this low PPS issue with good news. Tomorrow.
Bullish
MCRB Quote
AS OF 4/26/2023 3:09PM ET
$6.45 +$0.29 (+4.71%)
Volume
4,351,333
https://stockcharts.com/h-sc/ui?s=MCRB
Still waiting for FDA announcement. I was in one not so long ago that came at 11 PM. I'm too old to remember what that stock symbol was, lol
MCRB PDUFA today
Decision announced any time during day- probably after hours. Even very late in the evening
Company Profile
SectorHealth CareOpens in a new window
IndustryBiotechnologyOpens in a new window
Company LocationCambridge, MA
Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is SER-109, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes SER-109 product candidate, which is developed for the treatment of CDI and recurrent CDI; collaboration license agreement with Societe des Produits Nestle S.A. (Nestle) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease; research collaboration and option agreement with AstraZeneca Inc. for research and develop of microbiome in certain cancers and cancer immunotherapies, including research program for SER-401 targeting various cancers. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
www.serestherapeutics.com
0
MCRB countdown to tomorrow's PDUFA. Have you loaded?
https://stockcharts.com/h-sc/ui?s=MCRB
MG
MCRB Wednesday PDUFA
While we wait..
Weekend Music
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171755545
MCRB In today for PDUFA next week.
Have a great weekend, all!
MG
No rebuttal? Is this market even worldwide? Or am I on some fake market for just my pc?
I don't know why pharma wouldn't short this POS, if they cure recurrent c. diff it's no longer recurrent and so you aren't selling anything. Doesn't seem like the business model works at all.
It's like sellin' food with vitamins still in it when your competitors did a manual extraction and started selling a separate line of vitamin pills.
It's recurrent for a reason!
MCRB is a great $$$$$ opportunity.
Current shelf placement closes Monday, and generates over $200M .
Plus we have a huge new life saving drug coming to marketplace.
* * $MCRB Video Chart 08-13-2020 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 08-10-2020 * *
Link to Video - click here to watch the technical chart video
This is HUGE... I am an NP so I know!!
73k CDI episodes of 2+ recurrences/year in US as studied in current study. Another 100k/year primary recurrence cases being studied in open label extension trial. Will SER-109 eventually be studied and used for the other 439k/year CDI patients in US to prevent any recurrences?
MCRB discovers immortality = stock quadruples lol
Good grief chief $$$$$$$$$$$$
MCRB @ 19.39 up 317% >
16.95 up 275% in PM. > FDA phase III news!
Seres Therapeutics Phase 3 SER-109 Study Meets Main Endpoint >MCRB
7:06 am ET August 10, 2020 (Dow Jones) Print
By Colin Kellaher
Seres Therapeutics Inc. on Monday said a pivotal phase 3 study of its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection met its primary endpoint.
The Cambridge, Mass., developer of biological drugs said SER-109 showed a highly statistically significant 30.2% absolute reduction in the rate of C. difficile infection recurrence compared with placebo, adding that the drug was well tolerated, with a safety profile comparable to placebo.
Seres also said the study's efficacy results exceeded the U.S. Food and Drug Administration's statistical threshold that could allow the single study to fulfill efficacy requirements for a biologics license application, and the company said it plans to meet with the agency to discuss filing for product approval as soon as possible.
C. difficile, an antibiotic-resistant bacterium, is a leading cause of hospital-acquired infection in the U.S.
Shares of Seres, which closed Friday at $4.64, more than tripled to $14.20 in premarket trading Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
* * $MCRB Video Chart 06-29-2019 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 06-14-2019 * *
Link to Video - click here to watch the technical chart video
* * $MCRB Video Chart 03-11-2019 * *
Link to Video - click here to watch the technical chart video
10.71 BOL BAND ..SHOULD BOUNCE BACK DOWN FROM THAT...PLUS RSI HIGH = SELL
Marino, picking up nickels in front of a bulldozer...
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
356
|
Created
|
06/25/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |